PhotoPill Medical's Crohn's Disease study is now Actively Recruiting Participants for Groundbreaking Study on Inflammatory Bowel Disease (IBD)
Crohn’s is a condition that requires constant management and treatment, the IBD-Cap aims to significantly improve patient’s quality of life by delivering a much safer, medication-free treatment— Sharon Ben Yehuda
REHOVOT, ISRAEL, May 28, 2025 /
EINPresswire.com/ --
PhotoPill Medical, a leader in innovative therapeutic solutions for gastrointestinal diseases, announced today the initiation of the second part and the enrolment of the first patient, of a clinical study for its revolutionary IBD-Cap capsule, a novel non-pharmaceutical technology developed for the treatment of Crohn’s disease flare-ups. After successfully completing the safety part of the study - the study is now open and actively recruiting patients diagnosed with Crohn’s disease.
The IBD-Cap capsule represents a next-generation approach for managing inflammatory bowel diseases. Designed as a swallowable capsule, the IBD-Cap combines advanced technology and algorithms for delivering Photo-Bio-Modulation treatment (light) directly to the inflamed area within the intestine, with no medications or chemicals and with no expected side-effects.
“Crohn’s disease is a lifelong condition that requires constant management and treatment, and our IBD-Cap aims to significantly improve patient’s quality of life while delivering a much safer, medication-free treatment,” says Sharon Ben Yehuda, VP Clinical Research & Development at PhotoPill Medical. “This clinical study is a crucial step toward validating our technology and bringing it to the patients who need it most.”
The prospective study will evaluate the safety and effectiveness, of the IBD-Cap capsule in adults with mild-to-moderate small bowel Crohn’s disease. Participants will be monitored throughout the study period and their disease condition and feedback will be recorded to assess capsule performance.
Study Highlights:
• Currently enrolling adults diagnosed with mild-to-moderate Crohn’s disease
• Participation includes use of the IBD-Cap capsule along with standard care assessments
• Conducted at leading gastroenterology centers across Israel
• Designed to gather data on capsule safety, effectiveness, and patient outcomes
Patients, caregivers, and healthcare providers interested in learning more or participating in the study can contact sharon@photopill-med.com.
About PhotoPill Medical
PhotoPill Medical is a medical technology company dedicated to transforming gastrointestinal therapy through non-pharmaceutical, patient-centered innovations. With a mission to improve quality of life and disease condition for patients living with chronic GI diseases, PhotoPill Medical is developing a portfolio of smart treatment tools designed to empower clinicians and patients alike.
Ram Ben Yehuda
PhotoPill Medical
+972 50-562-6404
email us here